Kanto Rosai Hospital Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
1999
NCT00407225
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Alternative names

Director, Kanto Rosai Hospital | Director, Kanto Rosai Hospital; Director, Japanese Red Cross Medical Center

Active Ingredients

Drugs in Phase 2 Trials (1)

difluprednate (durezol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Inflammation (Phase 2)

Iridocyclitis (Phase 2)

Uveitis (Phase 2)

Uveitis, Anterior (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1